Clinical trials: HDV
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatitis D
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
- Trial name
- NCT01316185
- Testing
- EBP921
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Eiger BioPharmaceuticals
Chronic Hepatitis Delta
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants.
- Trial name
- NCT07096193
- Testing
- GS-4321
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic HDV Infection
A Clinical Study of HH-1270 in Healthy Chinese Subjects
This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.
- Trial name
- NCT07876440
- Testing
- HH-1270
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Huahui Health
Observe and Describe the Prevalence of Hepatitis D Infection Among HBsAg Positive People
Epidemiological Survey of Hepatitis D Virus Infection in China
This cross-sectional study will screen out hepatitis D virus-infected patients in HBsAg-positive people. Observe and describe the prevalence of hepatitis D infection among HBsAg positive people.
- Trial name
- NCT04483518
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The First Hospital of Jilin University
HDV, HDV Infection
D-SOLVE Cohorts (Cohort A and B)
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death.
- Conditions
- HDV, HDV Infection, Chronic Liver Disease
- Trial name
- HDV750 (NCT06160635)
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 750 people
- Sponsor
- Hannover Medical School
Chronic Viral Hepatitis B Without Delta-agent
Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B
With the availability of potent nucloes(t)ide analogues (NA), such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV), suppression of serum HBV DNA to undetectable levels by polymerase chain reaction (PCR) assays became…
- Trial name
- IN-US-0202 (NCT01639092)
- Testing
- Tenofovir, Entecavir
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- Asan Medical Center
Chronic Hepatitis Delta, Liver Biopsy
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
- Trial name
- NCT04170452
- Testing
- liver biopsy
- Where
- Uzbekistan
- Volunteers
- 30 people
- Sponsor
- Tokhirbek Dolimov
HIV Infection, HBV Infection
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
The VIROPREG study is a French prospective multicenter cohort study that aims to assess the impact of viral infections and antiviral treatments received during pregnancy on maternal and child health.
- Conditions
- HIV Infection, HBV Infection, HDV Infection, HCV Infection
- Trial name
- VIROPREG (NCT07412977)
- Testing
- Blood sampling, Umbilical cord blood sampling, Survey using a questionnaire
- Where
- France
- Volunteers
- 5,160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
- Trial name
- NCT07142811
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 31 sites in Belgium, Bulgaria and 9 more
- Volunteers
- 100 people
- Sponsor
- Vir Biotechnology, Inc.
Liver Disease, Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Background: Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research.
- Trial name
- NCT03600714
- Testing
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D
Burden of Hepatitis D Virus (HDV) Infection in Italy
The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced…
- Trial name
- HDV Describe (NCT05723068)
- Where
- 36 sites in Italy
- Volunteers
- 515 people
- Sponsor
- University of Turin, Italy
Chronic Viral Hepatitis B With Delta-Agent
Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study
The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective…
- Trial name
- NCT06068140
- Where
- 7 sites in Kazakhstan
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Hepatitis Delta Virus
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in patients chronically infected with HDV.
- Trial name
- LIMT-2 (NCT05070364)
- Testing
- Peginterferon Lambda-1a
- Where
- 48 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- Eiger BioPharmaceuticals
Chronic Hepatitis D Infection, Fibrosis, Liver
Find HDV and Determine Its Status in Turkey
The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast.
- Conditions
- Chronic Hepatitis D Infection, Fibrosis, Liver, Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- SITUHDVATION (NCT06248580)
- Testing
- Anti Delta
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Yaşar Bayındır, MD
Human Immunodeficiency Virus, HBV
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to…
- Conditions
- Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT02344680
- Testing
- Anti-HIV Agents
- Where
- Zambia
- Volunteers
- 349 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis D, Chronic
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
- Trial name
- LIMT (NCT02765802)
- Testing
- Peginterferon Lambda-1A
- Where
- 4 sites in Israel, New Zealand and 1 more
- Volunteers
- 33 people
- Sponsor
- EIT Pharma, Inc.
Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
- Trial name
- NCT06903338
- Testing
- Tobevibart, Elebsiran
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 124 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis Delta Virus Infection
A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05861674
- Testing
- HH-003(20mg/kg), HH-003(10mg/kg), TAF
- Where
- 7 sites in China, Pakistan
- Volunteers
- 101 people
- Sponsor
- Huahui Health